Clinical trials
Rectal Neoplasms trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Active, not recruiting | 5 |
| Terminated | 4 |
| Recruiting | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peter MacCallum Cancer Centre, Australia | 4 |
| Amgen | 2 |
| Novartis Pharmaceuticals | 2 |
| Pfizer | 2 |
| Trans Tasman Radiation Oncology Group | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| Corvus Pharmaceuticals, Inc. | 1 |
| DEM BioPharma, Inc. | 1 |
| Eisai Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rectal Neoplasms | 31 |
| Colonic Neoplasms | 21 |
| Colorectal Neoplasms | 18 |
| Neoplasm Metastasis | 6 |
| Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Endometrial Neoplasms | 3 |
| Lung Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 2 |
Trials
Showing 51 to 31 of 31. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.